Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) announced it has entered into a definitive agreement for a registered direct offering of 825,085 shares of common stock at $3.03 per share, generating approximately $2.5 million in gross proceeds before fees and expenses.

The Staten Island-based biopharmaceutical company will also issue unregistered short-term warrants to purchase up to 1.65 million additional shares at an exercise price of $2.78 per share. These warrants are immediately exercisable and expire 24 months after the effective date of the registration statement. If exercised in full, the warrants could generate an additional $4.6 million in gross proceeds.

H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering. The closing is expected to occur on or about April 16, 2026, subject to customary closing conditions.

The company stated it intends to use the net proceeds for working capital and general corporate purposes. The offering is being conducted under a shelf registration statement filed with the Securities and Exchange Commission in July 2025, which became effective in January 2026.

Acurx develops antibiotics for difficult-to-treat bacterial infections, with a focus on Gram-positive bacteria. The company's lead product candidate, ibezapolstat, is being developed for C. difficile infections and is described as Phase 3 ready for international clinical trials.

The short-term warrants are being issued through a concurrent private placement under Section 4(a)(2) of the Securities Act and have not been registered with the SEC.